These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 26298786

  • 1. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
    Bogan RK, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G, Khayrallah M, Lankford DA.
    Sleep Med; 2015 Sep; 16(9):1102-8. PubMed ID: 26298786
    [Abstract] [Full Text] [Related]

  • 2. Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
    Ruoff C, Swick TJ, Doekel R, Emsellem HA, Feldman NT, Rosenberg R, Bream G, Khayrallah MA, Lu Y, Black J.
    Sleep; 2016 Jul 01; 39(7):1379-87. PubMed ID: 27166238
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Identifying clinically important difference on the Epworth Sleepiness Scale: results from a narcolepsy clinical trial of JZP-110.
    Scrima L, Emsellem HA, Becker PM, Ruoff C, Lankford A, Bream G, Khayrallah M, Lu Y, Black J.
    Sleep Med; 2017 Oct 01; 38():108-112. PubMed ID: 29031743
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
    Dauvilliers Y, Shapiro C, Mayer G, Lammers GJ, Emsellem H, Plazzi G, Chen D, Carter LP, Lee L, Black J, Thorpy MJ.
    CNS Drugs; 2020 Jul 01; 34(7):773-784. PubMed ID: 32588401
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy.
    Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, Niebler GE, Roth T.
    Curr Med Res Opin; 2006 Apr 01; 22(4):761-74. PubMed ID: 16684437
    [Abstract] [Full Text] [Related]

  • 8. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
    Strollo PJ, Hedner J, Collop N, Lorch DG, Chen D, Carter LP, Lu Y, Lee L, Black J, Pépin JL, Redline S, Tones 4 Study Investigators.
    Chest; 2019 Feb 01; 155(2):364-374. PubMed ID: 30471270
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test.
    van der Heide A, van Schie MK, Lammers GJ, Dauvilliers Y, Arnulf I, Mayer G, Bassetti CL, Ding CL, Lehert P, van Dijk JG.
    Sleep; 2015 Jul 01; 38(7):1051-8. PubMed ID: 25902810
    [Abstract] [Full Text] [Related]

  • 11. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
    Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Chandler P, Lee L, Schwab R.
    Sleep; 2020 Feb 13; 43(2):. PubMed ID: 31691827
    [Abstract] [Full Text] [Related]

  • 12. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
    Emsellem HA, Thorpy MJ, Lammers GJ, Shapiro CM, Mayer G, Plazzi G, Chen D, Carter LP, Villa KF, Lee L, Menno D, Black J, Dauvilliers Y.
    Sleep Med; 2020 Mar 13; 67():128-136. PubMed ID: 31926465
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
    Black J, Swick T, Bogan R, Lai C, Carter LP.
    Sleep Med; 2016 Aug 13; 24():57-62. PubMed ID: 27810187
    [Abstract] [Full Text] [Related]

  • 15. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.
    Krystal AD, Benca RM, Rosenberg R, Schweitzer PK, Malhotra A, Babson K, Lee L, Bujanover S, Strohl KP.
    J Psychiatr Res; 2022 Nov 13; 155():202-210. PubMed ID: 36070638
    [Abstract] [Full Text] [Related]

  • 16. Correlation between the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test in patients with narcolepsy participating in two clinical trials of sodium oxybate.
    Erman M, Emsellem H, Black J, Mori F, Mayer G.
    Sleep Med; 2017 Oct 13; 38():92-95. PubMed ID: 29031763
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies.
    Davis CW, Kallweit U, Schwartz JC, Krahn LE, Vaughn B, Thorpy MJ.
    Sleep Med; 2021 May 13; 81():210-217. PubMed ID: 33721598
    [Abstract] [Full Text] [Related]

  • 19. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
    Dauvilliers Y, Mignot E, Del Río Villegas R, Du Y, Hanson E, Inoue Y, Kadali H, Koundourakis E, Meyer S, Rogers R, Scammell TE, Sheikh SI, Swick T, Szakács Z, von Rosenstiel P, Wu J, Zeitz H, Murthy NV, Plazzi G, von Hehn C.
    N Engl J Med; 2023 Jul 27; 389(4):309-321. PubMed ID: 37494485
    [Abstract] [Full Text] [Related]

  • 20. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
    Rosenberg R, Thorpy MJ, Dauvilliers Y, Schweitzer PK, Zammit G, Gotfried M, Bujanover S, Scheckner B, Malhotra A.
    J Clin Sleep Med; 2022 Jan 01; 18(1):235-244. PubMed ID: 34283019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.